Suchergebnisse - "Sessa, C"

PubPharm (422)

21

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2017

von Stathis, A. | Hess, D. | von Moos, R. | +12

22

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2017

von Stathis, A. | Hess, D. | von Moos, R. | +12

23

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2016

von Grilley-Olson, J. | Bedard, P. | Fasolo, A. | +13

24

Genetic susceptibility to cutaneous melanoma in southern Switzerland : role of CDKN2A, MC1R and MITF

enthalten in: The British journal of dermatology | 2016

von Mangas, C. | Potrony, M. | Mainetti, C. | +12

25

Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes : ESMO Clinical Practice Guidelines for cancer prevention and screening

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Paluch-Shimon, S. | Cardoso, F. | Sessa, C. | +5

ErratumIn: Ann Oncol. 2017 Jul 1;28(suppl_4):iv167-iv168. - PMID 28881931

26

appendix 7 : Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Ledermann, J. | Sessa, C. | Colombo, N. | +1

27

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

enthalten in: European journal of cancer (Oxford, England : 1990) | 2016

von Fiedler, W. | DeDosso, S. | Cresta, S. | +8

28

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2016

von Grilley-Olson, J. | Bedard, P. | Fasolo, A. | +13

29

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2016

von Grilley-Olson, J. | Bedard, P. | Fasolo, A. | +13

30

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2016

von Grilley-Olson, J. | Bedard, P. | Fasolo, A. | +13